Dimerix Limited Price Chart
Dimerix Limited DXB.XA Financial and Trading Overview
| Dimerix Limited stock price | 0.34 AUD |
| Previous Close | 0.06 AUD |
| Open | 0.06 AUD |
| Bid | 0.06 AUD x N/A |
| Ask | 0.06 AUD x N/A |
| Day's Range | 0.06 - 0.06 AUD |
| 52 Week Range | 0.06 - 0.18 AUD |
| Volume | 804K AUD |
| Avg. Volume | 251.02K AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 1.060153 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.037 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
DXB.XA Valuation Measures
| Enterprise Value | 12.94M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.8000002 |
| Enterprise Value/Revenue | 2.002 |
| Enterprise Value/EBITDA | -0.948 |
Trading Information
Dimerix Limited Stock Price History
| Beta (5Y Monthly) | 1.060153 |
| 52-Week Change | -57.77% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.18 AUD |
| 52 Week Low | 0.06 AUD |
| 50-Day Moving Average | 0.08 AUD |
| 200-Day Moving Average | 0.13 AUD |
DXB.XA Share Statistics
| Avg. Volume (3 month) | 251.02K AUD |
| Avg. Daily Volume (10-Days) | 346.95K AUD |
| Shares Outstanding | N/A |
| Float | 211.72M |
| Short Ratio | N/A |
| % Held by Insiders | 34.32% |
| % Held by Institutions | 4.14% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 0.05:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | -210.84% |
| Operating Margin (ttm) | -211.24% |
| Gross Margin | 100.00% |
| EBITDA Margin | -211.23% |
Management Effectiveness
| Return on Assets (ttm) | -63.49% |
| Return on Equity (ttm) | -117.16% |
Income Statement
| Revenue (ttm) | 6.47M AUD |
| Revenue Per Share (ttm) | 0.02 AUD |
| Quarterly Revenue Growth (yoy) | -48.10% |
| Gross Profit (ttm) | 6.47M AUD |
| EBITDA | -13658372 AUD |
| Net Income Avi to Common (ttm) | -13632698 AUD |
| Diluted EPS (ttm) | -0.037 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.71M AUD |
| Total Cash Per Share (mrq) | 0.02 AUD |
| Total Debt (mrq) | 47.79K AUD |
| Total Debt/Equity (mrq) | 0.99 AUD |
| Current Ratio (mrq) | 4.325 |
| Book Value Per Share (mrq) | 0.015 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10599796 AUD |
| Levered Free Cash Flow (ttm) | -5473225 AUD |
Profile of Dimerix Limited
| Country | Australia |
| State | VIC |
| City | Fitzroy |
| Address | 425 Smith Street |
| ZIP | 3065 |
| Phone | 1300 813 321 |
| Website | https://dimerix.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
Q&A For Dimerix Limited Stock
What is a current DXB.XA stock price?
Dimerix Limited DXB.XA stock price today per share is 0.34 AUD.
How to purchase Dimerix Limited stock?
You can buy DXB.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Dimerix Limited?
The stock symbol or ticker of Dimerix Limited is DXB.XA.
How many shares does Dimerix Limited have in circulation?
The max supply of Dimerix Limited shares is 0.
What is Dimerix Limited Price to Earnings Ratio (PE Ratio)?
Dimerix Limited PE Ratio is now.
What was Dimerix Limited earnings per share over the trailing 12 months (TTM)?
Dimerix Limited EPS is -0.037 AUD over the trailing 12 months.